Clinical Development for Cancer Genome Medicine in Advanced Non-Small-Cell Lung Cancer

DOI IR (HANDLE) Web Site Open Access
  • OKAMOTO Isamu
    Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • 進行非小細胞肺癌におけるゲノム医療の臨床開発
  • シンコウ ヒショウサイボウ ハイガン ニ オケル ゲノム イリョウ ノ リンショウ カイハツ

Search this article

Description

‘‘Cancer‘‘ is the leading cause of death in Japan. Among them, lung cancer is the leading cause of cancer death, and more than 70,000 patients die annually in Japan. Despite of lung cancer medical examination in Japan, more than half of them are inoperable advanced lung cancer with distant metastasis at the time of diagnosis, and for those patients, treatment with anticancer drugs is indicated. The treatment outcome for advanced lung cancer was extremely severe 20 years ago, with a median survival time of 12-15 months. However, in recent years, the introduction of molecular-targeted therapy based on genetic abnormalities has significantly improved treatment results, and many cases have been experienced in which daily life can be maintained for more than 5 years. This long-term progress in lung cancer treatment is based on the results of excellent basic molecular biology research and it is also noteworthy that the accumulation of high-quality investigator-initiated clinical trials have led to improved treatment results. Here, I am going to introduce how lung cancer drug treatment has progressed and what role investigator-initiated clinical trials have played in it, including a part of our research.

Journal

  • 福岡醫學雜誌

    福岡醫學雜誌 113 (1), 1-6, 2022-03-25

    Fukuoka Medical Association

Keywords

Details 詳細情報について

Report a problem

Back to top